Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Otsuka, Ionis Extend HAE Licensing Pact into Asia
June 19, 2024
- Kidswell Bio, Chiome Hook Up on Biosimilar Development
June 19, 2024
- Mitsubishi Offloads Argatroban Business in Europe to Ethypharm
June 19, 2024
- Daiichi Sankyo President Reels in 200 Million Yen-Plus Pay in FY2023
June 19, 2024
- Takeda Bags Option to Ascentage’s CML Drug
June 18, 2024
- Takeda’s Epilepsy Drug Misses Mark in Two PIII Studies
June 18, 2024
- Kunio Takeda, Former CEO of Takeda Pharmaceutical, Dies at 84
June 18, 2024
- India’s Biocon to Set Up Japan Office to Make Full Inroads into Generic API Sector
June 18, 2024
- MSD Files Prevymis for Pediatric Use, Granules Form in Japan
June 17, 2024
- Eisai CEO’s Son Promoted to Representative Officer & EVP
June 17, 2024
- Eisai CEO’s Pay Tops 200 Million Yen: Securities Report
June 17, 2024
- Bridion Generic Vials Hit Market in Droves at 32% of Originator Price
June 14, 2024
- Choseido Contract Manufactured Cephem Antibiotics for 8 Firms
June 14, 2024
- GSK to Discontinue Immediate-Release Versions of Paxil in Japan
June 14, 2024
- Pfizer Has High Hopes for Elrexfio/Prevenar 20, Rich ADC Assets after Seagen Deal
June 13, 2024
- Lilly Set to Raise Profile as Only Eczema Player with Oral and Injectable Options
June 13, 2024
- Astellas’ Gastric Cancer Drug Vyloy Now Available in Japan
June 13, 2024
- Ono Completes Acquisition of Deciphera
June 13, 2024
- En Route to 2030 Target, Shionogi to Carve Out New Biz in Areas with High Medical Needs
June 12, 2024
- Otsuka Resolved to Log 2.5 Trillion Yen in FY2028 by Offsetting Patent Cliffs with Novel Drugs
June 12, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…